Clinical Trials · NCT00326469

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Name: Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Lanreotide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 30
Start date: May 2006
Locations: 27 sites, Spain
Primary endpoint: Time to disease progression (appearance of 1+ new lesions or increase >or= to 20% of sum of the longest diameters of target lesions compared to the lower sum of maximum diameters recorded since the start of the study).

View Lanreotide compound reference